Work

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-115986

Authors: Graham P. Collins, Steven M. Horwitz, Andrew Davies, Anand Karnad, Felipe Samaniego, Alexander I Spira, Paul A Fields, Tobias Menne, Joseph Boni, Hans Cruz, Jay Feingold, Shui He, Jens Wuerthner, Mehdi Hamadani

Institutions: Oxford University Hospitals NHS Trust, Memorial Sloan Kettering Cancer Center, University of Southampton, Mays Cancer Center at UT Health San Antonio, The University of Texas MD Anderson Cancer Center, Virginia Cancer Specialists, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Adc Therapeutics (Switzerland), Medical College of Wisconsin

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2912279708

Cites:

Cited by: 19

Related to: 10